Skip to content

Molly Lennard-Jones

5 papers in the library · 413 citations · publishing 2021-2025

Papers

Sort Most recent Most cited

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions

American Journal of Psychiatry 2025 Namik Kirlic, Molly Lennard-Jones, Merve Atli et al. 27 citations

The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or...

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.

Journal of Affective Disorders April 1, 2023 Nadav Liam Modlin, Tammy M Miller, James J Rucker et al. 30 citations

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric...

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Journal of Affective Disorders February 3, 2023 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 168 citations

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

Journal of Psychopharmacology 2022 James Rucker, Lindsey Marwood, Riikka-Liisa Johanna Ajantaival et al. 101 citations

Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim: The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised...

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research

Frontiers in Psychiatry February 3, 2021 Sara Tai, Elizabeth M. Nielson, Molly Lennard-Jones et al. 87 citations

Introduction: Psychological support throughout psilocybin therapy is mandated by regulators as an essential part of ensuring participants' physical and psychological safety. There is an increased need for specially trained therapists who can provide high-quality care to participants in clinical studies. This paper describes the development and practical implementation of a therapist training...